Document Detail


Progesterone, progestins, and the heart.
MedLine Citation:
PMID:  21389912     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
All combination hormone replacement regimens contain estrogen and a progestational agent. The Women's Health Initiative trial demonstrated that taking the combination of conjugated estrogen and medroxyprogesterone resulted in a higher risk of myocardial infarction and stroke in the study population. However, not all progestational agents are alike in their cardiovascular properties. This article reviews what is known about the most commonly prescribed agents: progesterone, medroxyprogesterone, norethindrone, and norethindrone acetate. We compare data on markers of lipid metabolism, inflammation, and clotting function, and review studies that measure their direct effects on cardiac vessels.
Authors:
Paula Bernstein; Gerald Pohost
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Reviews in cardiovascular medicine     Volume:  11     ISSN:  1530-6550     ISO Abbreviation:  Rev Cardiovasc Med     Publication Date:  2010  
Date Detail:
Created Date:  2011-03-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960007     Medline TA:  Rev Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  228-36     Citation Subset:  IM    
Affiliation:
Cedars Sinai Medical Center, Los Angeles, CA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Infiltrative diseases of the heart.
Next Document:  Extra Long PR Intervals.